The innovation uses RNA interference to silence genes causing excessive inflammatory proteins, offering precision medicine instead of systemic symptom treatment. Liquid crystal nanoparticles protect genetic material and enable deep skin absorption, allowing multiple therapeutic RNAs and drugs to be combined in single particles.
USP desenvolve nanotecnologia de RNA para tratar psoríase e câncer de pele
Cobertura Relacionada
Análise sobre a necessidade de supervisão dos órgãos de controle institucional e suas implicações para a democracia e tr…
Google News · Aug 22 Botafogo negocia retorno do atacante Tiquinho SoaresBotafogo está em negociações para trazer de volta o atacante Tiquinho Soares. O clube busca reforçar seu elenco com o re…
Rádio Itatiaia · Aug 21 Uber cobra motoristas por corridas recusadas em teste europeuUber testa cobrança de taxa por corridas recusadas em cidades suecas e suíças, redefinindo o custo de estar disponível p…
Folha de S.Paulo · Aug 21 Buscas por suplementos alimentares batem recorde em 2026; Brasil lidera na América do SulBuscas por suplementos alimentares no Google atingem recorde em 2026, com Brasil liderando na América do Sul. Especialis…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
Brazilian USP researchers develop RNA nanotechnology for skin diseases with potential global medical applications, positioning Brazil as a biotech innovator in precision medicine.
Brazil strengthens its position in cutting-edge biotechnology and precision medicine, reducing dependence on foreign pharmaceutical solutions. Demonstrates South American scientific capacity and attracts international research partnerships and investment.
Similar to Brazil's earlier leadership in biofuels and agricultural biotechnology, positioning the nation as a regional scientific hub competing with developed nations in high-value biotech sectors.
Lente Económico
USP develops RNA nanotechnology platform using liquid crystal nanoparticles for targeted treatment of psoriasis and skin cancer, representing precision nanomedicine advancement with significant commercial potential in dermatology and biotechnology sectors.
Patients with psoriasis (5M in Brazil, 190M globally) and skin cancer could benefit from more effective, targeted treatments with fewer systemic side effects. Potential for improved quality of life and reduced healthcare costs through precision medicine approach rather than systemic medications.
Likely to attract increased R&D funding from Brazilian government agencies (FAPESP, CNPq). May accelerate regulatory pathways for nanomedicine approval. Could influence healthcare policy toward precision medicine reimbursement models. International collaboration opportunities may expand through technology transfer agreements.